Currently what's happening is that all of the costs are borne by taxpayer dollars for the entire framework.
If we're looking at the incremental increases from the cost recovery revenues, if we spread those costs across all Canadians—not just Canadians using products—if 100% of those costs were passed along by the industry to Canadians, that would be the equivalent of $1.60 per Canadian, regardless of whether they use the product or not. Again, it's really up to the companies what they do with those increased costs.
The $58,000 in terms of the fees, that's a class 3 product of the highest complexity, which is very novel and would take additional time. That's the minority.
The majority of products are class 1. The fee for a new product and seeking to market it in Canada would be just over $1,000. With the fee remissions for a small company, that would be $562. The equivalent of that for a pharmaceutical, prescription medication would be over $500,000 as a fee to Health Canada.